Communications to the Editor
J ournal of Medicinal Chemistry, 1999, Vol. 42, No. 15 2745
(7) For a review of the structural components of the PDH multien-
zyme complex, see: Mattevi, A.; De Kok, A.; Perham, R. N. The
Pyruvate Dehydrogenase Multienzyme Complex. Curr. Opin.
Struct. Biol. 1992, 2, 877-887.
(8) Sugden, P. H.; Kerbey, A. L.; Randle, P. J .; Waller, C. A.; Reid,
K. B. Amino Acid Sequences Around the Sites of Phosphorylation
in the Pig Heart Pyruvate Dehydrogenase Complex. Biochem.
J . 1979, 181, 419-426.
(9) Yeaman, S. J .; Hutcheson, E. T.; Roche, T. E.; Pettit, F. H.;
Brown, J . R.; Reed, L. J .; Watson, D. C.; Dixon, G. H. Sites of
Phosphorylation on Pyruvate Dehydrogenase from Bovine Kid-
ney and Heart. Biochemistry 1978, 17, 2364-2370.
(28) Halpert, J . R.; Balfour, C.; Miller, N. E.; Kaminsky, L. S.
Dichloromethyl Compounds as Mechanism-Based Inactivators
of Rat Liver Cytochromes P 450 In Vitro. Mol. Pharmacol. 1986,
30, 19-24.
(29) Bookstaff, R. C.; Moore, R. W.; Ingall, G. B.; Peterson, R. E.
Androgenic Deficiency in Male Rats Treated with Perfluorode-
canoic acid. Toxicol. Appl. Pharmacol. 1990, 104, 322-333.
(30) Espinal, J .; Leesnitzer, T.; Hassman, A.; Beggs, M.; Cobb, J .
Inhibition of Pyruvate Dehydrogenase Kinase by Halogenated
Acetophenones. Drug Devel. Res. 1995, 35, 130-136.
(31) J ackson, J . C.; Vinluan, C. C.; Dragland, C. J .; Sundararajan,
V.; Yan, B.; Gounarides, J . S.; Nirmala, N. R.; Topiol, S.; Ramage,
P.; Blume, J . E.; Aicher, T. D.; Bell, P. A.; Mann, W. R.
Heterologously Expressed Inner Lipoyl Domain of Dihydrolipoyl
Acetyltransferase Inhibits ATP-Dependent Inactivation of Pyru-
vate Dehydrogenase Complex: Identification of Important Amino
Acid Residues. Biochem. J . 1998, 334, 703-711.
(32) Ohnmacht, C. J .; Russell, K.; Empfield, J . R.; Frank, C. A.;
Gibson, K. H.; Mayhugh, D. R.; McLaren, F. M.; Shapiro, H. S.;
Brown, F. J .; Trainor, D. A.; Ceccarelli, C.; Lin, M. M.; Masek,
B. B.; Forst, J . M.; Harris, R. J .; Hulsizer, J . M.; Lewis, J . J .;
Silverman, S. M.; Smith, R. W.; Warwick, P. J .; Kau, S. T.; Chun,
A. L.; Grant, T. L.; Howe, B. B.; Li, J . H.; Trivedi, S.; Halterman,
T. J .; Yochim, C.; Dyroff, M. C.; Kirkland, M.; Neilson, K. L.
N-Aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP
Potassium Channel Openers. Modifications on the Western
Region. J . Med. Chem. 1996, 39, 4592-4601.
(33) (a) Brieden, W.; Naughton, A.; Robins, K.; Shaw, N.; Tinschert,
A.; Zimmermann, T. Enzymic Method for the Stereoselective
Preparation of (S)- or (R)-3,3,3-trifluoro-2-hydroxy-2-methylpro-
pionic acids. Ger. Offen. (b) Konigsberger, K.; Prasad, K.; Repic,
O. The Synthesis of (R)- and (S)-R-Trifluoromethyl-R-hydroxy-
carboxylic Acids via Enzymatic Resolutions. Tetrahedron Asym-
metry 1999, 10, 679-687.
(34) For the enzymatic resolution of the (S)-enantiomer, see: Crosby,
J .; Holt, R. A.; Pittam, J . D. Enzymatic Process for Stereoselec-
tive Preparation of Therapeutic Amides. WO9738124-A 97.10.16
(9744).
(10) (a) Popov, K. M.; Kedishvili, N. Y.; Zhao, Y.; Shimomura, Y.;
Crabb, D. W.; Harris, R. A. Primary Structure of Pyruvate
Dehydrogenase Kinase Establishes a New Family of Eukaryotic
Protein Kinases. J . Biol. Chem. 1993, 268, 26602-26606. (b)
Popov, K. M.; Kedishvili, N. Y.; Zhao, Y.; Gudi, R.; Harris, R. A.
Molecular Cloning of the p45 Subunit of Pyruvate Dehydroge-
nase Kinase. J . Biol. Chem. 1994, 269, 29720-29724. (c) Gudi,
R.; Bowker-Kinley, M. M.; Kedishvili, N. A.; Zhao, Y.; Popov, K.
M. Diversity of the Pyruvate Dehydrogenase Kinase Gene
Family in Humans. J . Biol. Chem. 1995, 270, 28989-28994.
(11) Linn, T. C.; Pettit, F. H.; Reed, L. J . R-Keto Acid Dehydrogenase
Complexes. X. Regulation of the Activity of the Pyruvate
Dehydrogenase Complex from Beef Kidney Mitochondria by
Phosphorylation and Dephosphorylation. Proc. Natl. Acad. Sci.
U.S.A. 1969, 62, 234-241.
(12) Cate, R. L.; Roche, T. E. A Unifying Mechanism for Stimulation
of Mammalian Pyruvate Dehydrogenasea Kinase by Reduced
Nicotinamide Adenine Dinucleotide, Dihydrolipoamide, Acetyl
Coenzyme A, or Pyruvate. J . Biol. Chem. 1978, 253, 496-503.
(13) Randle, P. J .; Kerbey, A. L.; Espinal, J . Mechanisms of Decreas-
ing Glucose Oxidation on Diabetes and Starvation: Role of Lipid
Fuel and Hormones. Diabetes Metab. Rev. 1988, 4, 623-638.
(14) Pratt, M. L.; Roche, T. E. Mechanism of Pyruvate Inhibition of
Kidney Pyruvate Dehydrogenasea Kinase and Synergistic Inhi-
bition by Pyruvate and ADP. J . Biol. Chem. 1979, 254, 7191-
7196.
(15) Whitehouse, S.; Cooper, R. H.; Randle, P. J . Mechanism of
Activation of Pyruvate Dehydrogenase by Dichloroacetate and
other Halogenated Carboxylic Acids. Biochem. J . 1974, 141,
761-774.
(16) Stacpoole, P. W.; Moore, G. W.; Kornhauser, D. M. Metabolic
Effects of Dichloroacetate in Patients with Diabetes Mellitus and
Hyperlipoproteinemia. N. Engl. J . Med. 1978, 298, 526-530.
(17) (a) Curry, S. H.; Chu, P. I.; Baumgartner, T. G.; Stacpoole, P.
W. Plasma Concentrations and Metabolic Effects of Intravenous
Sodium Dichloroacetate. Clin. Pharmacol. Ther. 1985, 37, 89-
93. (b) Wells, P. G.; Moore, G. W.; Rabin, D.; Wilkinson, G. R.;
Oates, J . A.; Stacpoole, P. W. Metabolic Effects and Pharmaco-
kinetics of Intravenously Administered Dichloroacetate in Hu-
mans. Diabetologia 1980, 19, 109-113.
(18) Bersin, R. M.; Stacpoole, P. W. Dichloroacetate as Metabolic
Therapy for Myocardial Ischemia and Failure. Am. Heart J .
1997, 134, 841-855.
(19) Preiser, J . C.; Moulart, D.; Vincent, J . L. Dichloroacetate
Administration in the Treatment of Endotoxic Shock. Circ. Shock
1990, 36, 221-228.
(20) Granot, H.; Steiner, I. Successful Treatment of Irreversible
Hemorrhagic Shock in Dogs with Fructose-1,6-Diphosphate and
Dichloroacetate. Circ. Shock 1985, 15, 163-173.
(21) Henderson, G. N.; Curry, S. H.; Derendorf, H.; Wright, E. C.;
Stacpoole, P. W. Pharmacokinetics of Dichloroacetate in Adult
Patients with Lactic Acidosis. J . Clin. Pharmacol. 1997, 37, 416-
425.
(22) Bersin, R.; Kwasman, M.; DeMarco, T.; Lau, D.; Klinski, C.;
Golonka, J .; Chatterjee, K. Improved Hemodynamic Function
in Congestive Heart Failure with the Metabolic Agent Sodium
Dichloroacetate (DCA). J . Am. Coll. Cardiol. 1990, 15, 157A.
(23) Dichloroacetic acid showed efficacy in these indications. For a
review of the pharmacology of DCA, see: Stacpoole, P. W. The
Pharmacology of Dichloroacetate. Metabolism 1989, 38, 1124-
1144.
(24) Stacpoole, P. W.; Moore, G. W.; Kornhauser, D. M. Toxicity of
Chronic Dichloroacetate. N. Engl. J . Med. 1979, 300, 372.
(25) Yount, E. A.; Felten, S. Y.; O’Connor, B. L.; Peterson, R. G.;
Powell, R. S.; Yum, M. N.; Harris, R. A. Comparison of the
Metabolic and Toxic Effects of 2-Chloropropionate and Dichlo-
roacetate. J . Pharmacol. Exp. Ther. 1982, 222, 501-508.
(26) Katz, R.; Tai, C. N.; Diener, R. M.; McConnell, R. F.; Semonick,
D. E. Dichloroacetate, Sodium: 3-Month Oral Toxicity Studies
in Rats and Dogs. Toxicol. Appl. Pharmacol. 1987, 57, 273-287.
(27) Toth, G. P.; Kelty, K. C.; George, E. L.; Read, E. J .; Smith, M.
K. Adverse Male Reproductive Effects Following Subchronic
Exposure of Rats to Sodium Dichloroacetate. Fundam. Appl.
Toxicol. 1992, 19, 57-63.
(35) Kelly, S. E.; LaCour, T. G. A One Pot Procedure For the
Synthesis of R-Hydroxyamides from the Corresponding R-Hy-
droxyacids. Synth. Commun. 1992, 22, 859-869.
(36) Desai, M.; Watthey, J . W. H.; Zuckerman, M. A Convenient
Preparation of 1-Aroylpiperazines. Org. Prep. Proced. Int. 1976,
8, 85-86.
(37) (a) Bolos, J .; Gubert, S.; Anglada, L.; Planas, J . M.; Burgarolas,
C.; Castello, J . M.; Sacristan, A.; Ortiz, J . A. 7-[3-(1-Piperidinyl)-
propoxy]chromenones as Potential Atypical Antipsychotics. J .
Med. Chem. 1996, 39, 2962-2970. (b) Morikawa, A.; Sone, T.;
Asano, T. 5-Isoquinolinesulfonamide Derivatives. III. Synthesis
and Vasodilatory Activity of 1-(5-Isoquinolinesulfonyl)piperazine
Derivatives. Chem. Pharm. Bull. 1992, 40, 770-773.
(38) For the use of the 2-nitrobenzenesulfonyl moiety as a protecting
group for amines, see: (a) Fukuyama, T.; J ow, C.-K.; Cheung,
M. 2- and 4-Nitrobenzenesulfonamides: Exceptionally Versatile
Means for Preparation of Secondary Amines and Protection of
Amines. Tetrahedron Lett. 1995, 36, 6373-6374. (b) Fukuyama,
T.; Cheung, M.; J ow, C.-K.; Hidai, Y.; Kan, T. 2,4-Dinitroben-
zenesulfonamides: A Simple and Practical Method for the
Preparation of a Variety of Secondary Amines and Diamines.
Tetrahedron Lett. 1997, 38, 5831-5834.
(39) Craig, J . C.; Young, R. J . 1-Benzylpiperazine. Organic Syntheses;
Wiley: New York, 1962; Collect. Vol. V, pp 88-91.
(40) Available from Sigma Aldrich Corp., Milwaukee, WI (cat.#
P-7032).
(41) Inhibition of cAMP-dependent protein kinase was determined
using a colorimetric cAMP-dependent protein kinase (PKA)
assay kit (Pierce, Rockford, IL; cat.# 26500, SpinZyme format).
(42) Young, P. R.; McLaughlin, M. M.; Kumar, S.; Kassis, S.; Doyle,
M. L.; McNulty, D.; Gallagher, T. F.; Fisher, S.; McDonnell, P.
C.; Carr, S. A.; Huddleston, M. J .; Seibel, G.; Porter, T. G.; Livi,
G. P.; Adams, J . L.; Lee, J . C. Pyridinyl Imidazole Inhibitors of
p38 Mitogen-activated Protein Kinase Bind in the ATP site. J .
Biol. Chem. 1997, 272, 12116-12121.
(43) Stock, J . B.; Ninfa, A. J .; Stock, A. M. Protein Phosphorylation
and Regulation of Adaptive Responses in Bacteria Microbiol.
Rev. 1989, 53, 450-490.
(44) An NMR structural determination of the catalytic domain of a
prokaryotic histidine protein kinase has been completed; see:
Tanaka, T.; Saha, S. K.; Tomomori, C.; Ishima, R.; Liu, D.; Tong,
K. I.; Park, H.; Dutta, R.; Qin, L.; Swindells, M. B.; Yamazaki,
T.; Ono, A. M.; Kainosho, M.; Inouye, M.; Ikura, M. NMR
Structure of the Histidine Kinase Domain of the E. coli Osmo-
sensor EnvZ. Nature 1998, 396, 88-92.
(45) Hanks, S. K. Eukaryotic Protein Kinases. Curr. Opin. Struct.
Biol. 1991, 1, 369-383.
(46) The SAR of the anilides and the design strategy used to optimize
them will be discussed in a full report; see: Aicher, T. D.;